Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 ...
02 Maio 2018 - 8:30AM
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an
ophthalmology-focused pharmaceutical company, today announced it
will release first quarter 2018 financial results after the close
of trading on Tuesday, May 15, 2018. The company will host a
conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
on the same day to discuss the financial results and recent
business developments.
To participate in the call, please dial (877)
407-8031 for domestic callers or (201) 689-8031 for international
callers. To listen to the webcast, please click here or visit
the investor relations section of the Imprimis website by clicking
here. A dial in replay of the call will be available until
June 15, 2018. To access the replay, dial (877) 481-4010
domestically or (919) 882-2331 internationally and reference Replay
ID: 29148. The webcast replay will be available until August
15, 2018.
About Imprimis
Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is
dedicated to making high-quality innovative medications accessible
and affordable. The company’s flexible business model allows
a drug to be compounded or developed as an FDA-approved product
through one of its subsidiaries or deconsolidated companies.
For more information about Imprimis, please visit the Investor
Relations section of the corporate website by clicking here.
SAFE HARBOR
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is
FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all Imprimis compounded formulations require
a prescription for an individually identified patient consistent
with federal and state laws.
Source: Imprimis Pharmaceuticals, Inc.
CONTACTS
Investor Contact:
Jon Patton
jpatton@imprimispharma.com
858-704-4587
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024